Key result
Cardiac rehabilitation yields smaller metabolic syndrome reductions in diabetic CHD patients, achieving an absolute ~3% drop.
Why the study?
Because type 2 diabetes and metabolic syndrome are highly prevalent in CHD patients attending CR, this study aimed to determine the prevalence of cardiometabolic derangements and compare post-CR clinical responses between patients with and without diabetes.
Does a 12-week multidisciplinary cardiac rehabilitation program improve metabolic syndrome prevalence and cardiometabolic risk factors to a similar extent in coronary heart disease patients with type 2 diabetes compared to those without diabetes?
Cohort (n=3,953)
No
Does a 12-week multidisciplinary cardiac rehabilitation program improve metabolic syndrome prevalence and cardiometabolic risk factors to a similar extent in coronary heart disease patients with type 2 diabetes compared to those without diabetes?
While a 12-week cardiac rehabilitation program improves cardiorespiratory fitness and reduces metabolic syndrome and insulin resistance in coronary heart disease patients regardless of diabetes status, patients with diabetes experience blunted cardiometabolic improvements and may require more aggressive, tailored risk factor and weight management.
Answers are grounded in this paper and cite their sources.
Smaller metabolic syndrome reductions after cardiac rehabilitation in diabetics suggest tailored programs may be needed; leaves open efficacy of intensified interventions in randomized trials.
BACKGROUND: Type 2 diabetes and cardiometabolic comorbidities manifesting as the metabolic syndrome (MetS) are highly prevalent in coronary heart disease (CHD) patients attending cardiac rehabilitation (CR). The study aimed to determine the prevalence of cardiometabolic derangements and MetS, and compare post-CR clinical responses in a large cohort of CHD patients with and without diabetes. METHODS: Analyses were conducted on 3953 CHD patients [age: 61.1 ± 10.5 years; 741 (18.7%) with diabetes] that completed a representative 12-week CR program. A propensity model was used to match patients with diabetes (n = 731) to those without diabetes (n = 731) on baseline and clinical characteristics. RESULTS: Diabetic patients experienced smaller improvements in metabolic parameters after completing CR, including abdominal obesity, and lipid profiles (all P ≤ .002), compared to non-diabetic patients. For both groups, there were similar improvement rates in peak metabolic equivalents ([METs]; P < .001); however, peak METs remained lower at 12-weeks in patients with diabetes than without diabetes. At baseline, the combined prevalence of insulin resistance (IR) and diabetes was 57.3%, whereas IR was present in 48.2% of non-diabetic patients, of which rates were reduced to 48.2% and 32.8% after CR, respectively. Accordingly, MetS prevalence decreased from 25.5% to 22.3% in diabetic versus 20.0% to 13.4% in non-diabetic patients (all P ≤ .004). CONCLUSIONS: Completing CR appears to provide comprehensive risk reduction in cardio-metabolic parameters associated with diabetes and MetS; however, CHD patients with diabetes may require additional and more aggressive attention towards all MetS criteria over the course of CR in order to prevent future cardiovascular events.
No takes yet. Share an insight, caveat, or question.
Laddu et al. (2019) conducted a cohort in Coronary heart disease (n=3,953). Type 2 diabetes status during a 12-week multidisciplinary cardiac rehabilitation program vs. Patients without diabetes completing the same 12-week cardiac rehabilitation program was evaluated on Absolute reduction in metabolic syndrome (MetS) prevalence after 12-week cardiac rehabilitation (p=<0.01). Cardiac rehabilitation reduced metabolic syndrome prevalence in coronary heart disease patients with diabetes, though less than in non-diabetic patients.
Synapse has enriched 10 related papers. Consider them for comparative context: